RPRX

Royalty Pharma's stock (RPRX) increased by 58.47% over the last 12 months and showed a year-to-date return of 47.93% as of October 3, 2026, though it decreased by 10.52% in the month prior. Key events include the acquisition of a royalty interest in Ziihera for $250 million and a commitment of up to $500 million to co-fund a Teva Pharmaceuticals program in January 2026. In March 2026, the company partnered with Johnson & Johnson, providing $500 million for autoimmune medicine development. Strong first-quarter 2026 financial results, including double-digit growth in Royalty Receipts and Portfolio Receipts, were reported on May 6, 2026, leading to raised full-year guidance. On August 5, 2026, second-quarter earnings showed a 14% increase in Royalty Receipts and doubled operating cash flow, resulting in a second raise in full-year guidance, despite a modest stock reaction. Insider selling by EVP Marshall Urist and Christopher Hite, totaling approximately $12.3 million, was reported in September/October 2026. October 2026 news included a $100 million rusfertide funding deal with Zealand and a $7.5 million gift to Blood Cancer United, with analyst firms raising price targets and maintaining a 'Buy' consensus, though a pelacarsen trial failure was noted as an offset.